Tom Frohlich, Jade Biosciences CEO
October 31, 2024 02:21 PM EDT
Startups
Deals

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

Kyle LaHucik

Senior Reporter

This week, biotech builder Paragon Ther­a­peu­tics took two of its port­fo­lio com­pa­nies pub­lic through re­verse merg­ers — Cres­cent Bio­phar­ma and now

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times